X4 Pharmaceuticals Inc.
XFOR | NASDAQ
$3.50
-$0.08 (-2.23%)
Sep 21, 2026, 4:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 35.11M | 2.56M | n/a | n/a | n/a | 3M |
Cost of Revenue | 6.26M | 797K | n/a | n/a | 1.89M | 1.23M |
Gross Profit | 28.86M | 1.76M | n/a | n/a | -1.89M | 1.77M |
Operating Income | -86.88M | -36.4M | -107.52M | -87.57M | -75.35M | -59.87M |
Interest Income | 4.58M | 5.77M | 4.58M | 219K | 10K | 273K |
Pretax Income | -79.16M | -37.14M | -101.09M | -93.84M | -88.68M | -61.98M |
Net Income | -79.2M | -37.45M | -101.17M | -93.87M | -88.7M | -62.13M |
Selling & General & Admin | 43.52M | 61.52M | 35.51M | 27.02M | 24.7M | 20.94M |
Research & Development | 72.22M | 81.64M | 72.02M | 61.06M | 48.76M | 40.7M |
Other Expenses | n/a | -105M | n/a | -509K | n/a | n/a |
Operating Expenses | 115.74M | 38.16M | 107.52M | 87.57M | 73.46M | 61.64M |
Interest Expense | 8.88M | 8.77M | 5.78M | 3.99M | 3.64M | 2.69M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 122M | 38.96M | 107.52M | 87.57M | 75.35M | 62.87M |
Income Tax Expense | 41K | 310K | 78K | 28K | 17K | 148K |
Shares Outstanding (Basic) | 42.29M | 6.7M | 5.93M | 2.12M | 858.3K | 669.23K |
Shares Outstanding (Diluted) | 42.29M | 6.7M | 5.93M | 2.12M | 858.3K | 669.23K |
EPS (Basic) | -1.87 | -5.59 | -17.07 | -45.60 | -119.58 | -92.84 |
EPS (Diluted) | -1.87 | -5.59 | -17.07 | -45.60 | -119.58 | -92.84 |
EBITDA | -69.01M | -27.58M | -94.89M | -89.33M | -83.15M | -58.64M |
EBIT | -70.28M | -28.37M | -95.31M | -89.85M | -85.04M | -59.87M |
Depreciation & Amortization | 1.28M | 796K | 419K | 513K | 1.89M | 1.23M |
Add to Watchlist
Select watchlists to add or remove XFOR